دورية أكاديمية
أعرض في EDS

A Multi-Faceted Analysis Showing CRNDE Transcripts and a Recently Confirmed Micropeptide as Important Players in Ovarian Carcinogenesis.

التفاصيل البيبلوغرافية
العنوان: A Multi-Faceted Analysis Showing CRNDE Transcripts and a Recently Confirmed Micropeptide as Important Players in Ovarian Carcinogenesis.
المؤلفون: Balcerak A; Department of Pathology and Anatomical Sciences, State University of New York, Buffalo, NY 14203, USA.; Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland., Szafron LA; Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland., Rubel T; Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, 00-665 Warsaw, Poland., Swiderska B; Mass Spectrometry Laboratory, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland., Bonna AM; Triple Helical Peptides Ltd., Cambridge CB22 5DU, UK., Konarzewska M; Department of Forensic Medicine, Warsaw Medical University, 02-007 Warsaw, Poland., Sołtyszewski I; Department of Forensic Medicine, Warsaw Medical University, 02-007 Warsaw, Poland., Kupryjanczyk J; Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland., Szafron LM; Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 16; Vol. 25 (8). Date of Electronic Publication: 2024 Apr 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/metabolism , Ovarian Neoplasms*/pathology , RNA, Long Noncoding*/genetics , RNA, Long Noncoding*/metabolism , Carcinogenesis*/genetics , Carcinogenesis*/metabolism, Humans ; Female ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Cell Proliferation
مستخلص: CRNDE is considered an oncogene expressed as long non-coding RNA. Our previous paper is the only one reporting CRNDE as a micropeptide-coding gene. The amino acid sequence of this micropeptide (CRNDEP) has recently been confirmed by other researchers. This study aimed at providing a mass spectrometry (MS)-based validation of the CRNDEP sequence and an investigation of how the differential expression of CRNDE(P) influences the metabolism and chemoresistance of ovarian cancer (OvCa) cells. We also assessed cellular localization changes of CRNDEP, looked for its protein partners, and bioinformatically evaluated its RNA-binding capacities. Herein, we detected most of the CRNDEP sequence by MS. Moreover, our results corroborated the oncogenic role of CRNDE , portraying it as the gene impacting carcinogenesis at the stages of DNA transcription and replication, affecting the RNA metabolism, and stimulating the cell cycle progression and proliferation, with CRNDEP being detected in the centrosomes of dividing cells. We also showed that CRNDEP is located in nucleoli and revealed interactions of this micropeptide with p54, an RNA helicase. Additionally, we proved that high CRNDE(P) expression increases the resistance of OvCa cells to treatment with microtubule-targeted cytostatics. Furthermore, altered CRNDE(P) expression affected the activity of the microtubular cytoskeleton and the formation of focal adhesion plaques. Finally, according to our in silico analyses, CRNDEP is likely capable of RNA binding. All these results contribute to a better understanding of the CRNDE(P) role in OvCa biology, which may potentially improve the screening, diagnosis, and treatment of this disease.
References: Cell. 2015 Feb 12;160(4):595-606. (PMID: 25640239)
Cell Death Dis. 2017 Jun 8;8(6):e2862. (PMID: 28594403)
Exp Mol Pathol. 2018 Feb;104(1):19-25. (PMID: 29246789)
Anticancer Agents Med Chem. 2008 Dec;8(8):843-56. (PMID: 19075567)
Leukemia. 2021 Jun;35(6):1710-1721. (PMID: 32879426)
Mol Cell. 2022 Aug 4;82(15):2885-2899.e8. (PMID: 35841888)
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):6855-62. (PMID: 26034286)
Cancer Biol Ther. 2004 Dec;3(12):1208-11. (PMID: 15662116)
Cell Death Dis. 2017 Aug 10;8(8):e2997. (PMID: 28796262)
J Mol Biol. 2002 Jan 25;315(4):911-25. (PMID: 11812157)
J Cell Mol Med. 2018 Dec;22(12):5862-5876. (PMID: 30246921)
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188556. (PMID: 33932560)
EMBO J. 2014 May 2;33(9):981-93. (PMID: 24705786)
J Hematol Oncol. 2017 Feb 18;10(1):50. (PMID: 28214467)
Cell. 2015 Oct 22;163(3):712-23. (PMID: 26496610)
Mol Biol Cell. 2019 Dec 1;30(25):3024-3036. (PMID: 31644363)
Methods Mol Biol. 2016;1413:403-21. (PMID: 27193863)
Trends Cell Biol. 2017 Sep;27(9):685-696. (PMID: 28528987)
Mol Biol Cell. 2015 Jul 15;26(14):2579-95. (PMID: 25995375)
Front Cell Dev Biol. 2021 Feb 04;9:599065. (PMID: 33614640)
PLoS Genet. 2006 Apr;2(4):e52. (PMID: 16683031)
Contemp Oncol (Pozn). 2015;19(5):350-3. (PMID: 26793017)
Am J Transl Res. 2017 Apr 15;9(4):1977-1989. (PMID: 28469804)
Cell Stress Chaperones. 2019 Jan;24(1):17-27. (PMID: 30506376)
J Biomol Tech. 2018 Jul;29(2):25-38. (PMID: 29805321)
Tumour Biol. 2016 Oct 6;:. (PMID: 27714674)
Neoplasma. 2018 Nov 15;65(6):872-880. (PMID: 30334449)
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6. (PMID: 25605897)
Oncotarget. 2015 Dec 22;6(41):43897-910. (PMID: 26556866)
PLoS One. 2015 May 15;10(5):e0127475. (PMID: 25978564)
Molecules. 2017 Nov 23;22(12):. (PMID: 29168755)
J Funct Biomater. 2015 Jul 16;6(3):598-622. (PMID: 26193326)
Mol Cell Biochem. 2022 May;477(5):1477-1488. (PMID: 35166986)
J Gynecol Oncol. 2022 Jul;33(4):e50. (PMID: 35557033)
Nat Rev Genet. 2014 Mar;15(3):193-204. (PMID: 24514441)
BMC Genomics. 2013 Feb 28;14:141. (PMID: 23448259)
Bioengineered. 2021 Dec;12(2):9290-9300. (PMID: 34806539)
Cancer Metastasis Rev. 2020 Sep;39(3):805-823. (PMID: 32385714)
Histopathology. 2015 Oct;67(4):538-47. (PMID: 25728258)
J Immunol. 2011 Dec 1;187(11):5824-33. (PMID: 22043013)
Eur Rev Med Pharmacol Sci. 2017 Dec;21(23):5392-5398. (PMID: 29243780)
Chem Biol. 1995 Sep;2(9):569-73. (PMID: 9383460)
Cold Spring Harb Perspect Biol. 2016 Dec 1;8(12):. (PMID: 27908937)
Oncol Res. 2018 Sep 14;26(8):1245-1255. (PMID: 28550688)
Curr Drug Targets. 2018;19(15):1801-1817. (PMID: 29336259)
Onco Targets Ther. 2018 Jun 29;11:3755-3763. (PMID: 29988699)
J Biol Chem. 2002 Oct 18;277(42):39777-85. (PMID: 12183452)
BMC Biol. 2011 Aug 11;9:54. (PMID: 21834987)
Cancer Biol Ther. 2012 Feb 1;13(3):156-63. (PMID: 22353935)
J Cell Sci. 2002 May 1;115(Pt 9):1815-24. (PMID: 11956313)
Oncoimmunology. 2018 Jul 23;7(10):e1488359. (PMID: 30288354)
Transl Oncol. 2022 Feb;16:101332. (PMID: 34973570)
Food Chem Toxicol. 2009 Mar;47(3):561-70. (PMID: 19138722)
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319)
PLoS One. 2022 Jul 22;17(7):e0271539. (PMID: 35867729)
Anticancer Res. 2015 Apr;35(4):2423-9. (PMID: 25862909)
Clin Exp Pharmacol Physiol. 2017 Aug;44(8):895-902. (PMID: 28477368)
RNA. 2021 Sep;27(9):1082-1101. (PMID: 34193551)
Cytometry A. 2010 Aug;77(8):733-42. (PMID: 20653013)
Front Cell Dev Biol. 2020 Nov 10;8:588801. (PMID: 33240887)
Cell Physiol Biochem. 2017;41(6):2489-2502. (PMID: 28472810)
Cell. 2013 Jul 3;154(1):240-51. (PMID: 23810193)
Front Genet. 2018 Apr 25;9:144. (PMID: 29922328)
Mol Cancer. 2017 Jan 13;16(1):9. (PMID: 28086904)
Biomed Pharmacother. 2018 Jul;103:1187-1193. (PMID: 29864897)
Prog Mol Biol Transl Sci. 2014;126:135-54. (PMID: 25081617)
Curr Biol. 2002 Nov 19;12(22):1928-33. (PMID: 12445386)
Mol Cancer Ther. 2006 Nov;5(11):2606-12. (PMID: 17088437)
FEBS J. 2013 Jan;280(1):256-72. (PMID: 23164465)
J Cell Biochem. 2019 Feb;120(2):1156-1164. (PMID: 30430650)
معلومات مُعتمدة: 2015/17/N/NZ5/01392 National Science Center; 2016/23/D/NZ5/01453 National Science Center; 2020/37/B/NZ5/04215 National Science Center
فهرسة مساهمة: Keywords: CRNDE; RNA-Seq; SEP; adhesion; affinity chromatography; centrosome; cytoskeleton; lncRNA; mass spectrometry; micropeptide; microtubule; nucleolus; ovarian cancer
المشرفين على المادة: 0 (RNA, Long Noncoding)
0 (CRNDE RNA, human)
تواريخ الأحداث: Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240429
رمز التحديث: 20240429
مُعرف محوري في PubMed: PMC11050281
DOI: 10.3390/ijms25084381
PMID: 38673965
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25084381